Recurrent deletions at the 22q11.2 locus have been established as a strong genetic risk factor for the development of schizophrenia and cognitive dysfunction. Individuals with 22q11.2 deletions have a range of well-defined volumetric abnormalities in a number of critical brain structures. A mouse model of the 22q11.2 deletion (Df(16)A þ / À ) has previously been utilized to characterize diseaseassociated abnormalities on synaptic, cellular, neurocircuitry, and behavioral levels. We performed a high-resolution MRI analysis of mutant mice compared with wild-type littermates. Our analysis revealed a striking similarity in the specific volumetric changes of Df(16)A þ / À mice compared with human 22q11.2 deletion carriers, including in cortico-cerebellar, cortico-striatal and cortico-limbic circuits. In addition, higher resolution magnetic resonance imaging compared with neuroimaging in human subjects allowed the detection of previously unknown subtle local differences. The cerebellar findings in Df(16)A þ / À mice are particularly instructive as they are localized to specific areas within both the deep cerebellar nuclei and the cerebellar cortex. Our study indicates that the Df(16)A þ / À mouse model recapitulates most of the hallmark neuroanatomical changes observed in 22q11.2 deletion carriers. Our findings will help guide the design and interpretation of additional complementary studies and thereby advance our understanding of the abnormal brain development underlying the emergence of 22q11.2 deletion-associated psychiatric and cognitive symptoms.
INTRODUCTION
The 22q11.2 deletions occur in B1 in 2000-4000 live births. 1 The vast majority of them (B90%) are three megabases (Mb) in size and contain B60 known genes, whereas a smaller fraction (B8%) are 1.5 Mb in size and contain B28 known genes. 1 Most of the genes in the 22q11.2 locus are expressed in the brain throughout development (http://www.brain-map.org/).
The phenotype associated with 22q11.2 deletions is variable. 1 Phenotypic variability may be partially due to breakpoint heterogeneity or other genetic, environmental and stochastic factors. A strong link has been established between 22q11.2 deletions, cognitive dysfunction and psychiatric disorders. Children with the deletions have specific behavioral impairments and exhibit a spectrum of deficits in cognitive abilities. 1 Adults with 22q11.2 deletions have a high risk of developing schizophrenia, approximately 25-31 times that of the general population. Indeed, 22q11.2 deletions are consistently found enriched in schizophrenia cohorts 2 accounting for 1-2% of non-familial (that is, sporadic) cases of schizophrenia. 3, 4 In contrast, no such enrichment has been reported in cohorts of patients with autism spectrum disorders 5 or bipolar disorder. 6 Furthermore, it has been suggested that the 1.5 Mb deletion is the minimal region that contains most of the genes that can account for the increased risk of schizophrenia among 22q11.2 deletion carriers. 1, 3 A mouse model carrying a hemizygous 1.3-Mb chromosomal deficiency (Df(16)A þ / À ) syntenic to the 1.5-Mb human 22q11.2 deletion and encompassing 27 genes has been previously generated and extensively investigated. [7] [8] [9] [10] [11] [12] Behavioral characterization of the Df(16)A þ / À mice has revealed specific deficits in sensorimotor gating, working memory and fear conditioning. 13 Furthermore, several studies of the Df(16)A þ / À mice have consistently shown modest differences in corticogenesis, relatively widespread deficits in dendritic complexity and spine density, as well as region-specific alterations in short-and long-term synaptic plasticity. Df(16)A þ / À mice also demonstrate a diminished synchrony between the hippocampus and medial prefrontal cortex activity during a task that relies on communication between these two structures, indicative of long-range functional connectivity impairments resulting from 22q11.2 deletions.
Owing to the high evolutionary conservation between the human 22q11.2 locus and the syntenic region on mouse chromosome 16, Df(16)A þ / À disrupts most of the crucial genes underlying the 22q11.2-associated phenotypes 13 ensuring strong construct validity of the mouse model. Whether this model also shows strong face validity, that is, recapitulation of some of the essential features of the disorder in humans, is more difficult to establish. Behavioral assays suggest that Df(16)A þ / À mice and 22q11.2 deletion carriers share deficits in some broadly defined cognitive domains. However, compared with behavior, neuroanatomical features are generally more directly associated with the mutation and more highly analogous between mouse models and human subjects. 14 Indeed, various neuroanatomical phenotypes have been traditionally used to establish face validity in genetic mouse models of neurological disorders such as Huntington's disease, Alzheimer's disease and Parkinson's disease. [15] [16] [17] Similarly, replication of key neuroanatomical findings in genetic mouse models of neuropsychiatric and neurodevelopmental diseases is important for three reasons: First, it can provide confidence that a mouse model recapitulates the core pathophysiology of the disease and can therefore be useful in furthering our understanding of disease etiology. Second, it can provide reliable biomarkers that can facilitate translational studies including drug development efforts. Third, high-resolution magnetic resonance imaging (MRI) is capable of detecting very subtle differences in the brain structure and volume, allowing a more detailed examination of neuroanatomical features compared with human subjects. 18, 19 High-resolution neuroanatomical phenotyping has enabled the detection of subtle volumetric brain changes in 17 mouse models in a sample of 19 different mouse behavioral mutants 20 and more recently in a number of genetic mouse models related to autism spectrum disorders, including Fragile X Syndrome, 21 16p11.2 deletion 22 and Neuroligin R541 knockin. 23 22q11.2 deletion carriers show a range of well-defined neuroanatomical abnormalities, 2, 11, 24 for which noninvasive brain imaging studies have replicated specific volumetric and structural brain alterations. These include ventricular enlargement, a decrease in volume of both cerebral and cerebellar cortices, and an increase in striatal volume. Interestingly, some of these neuroanatomical findings have also been described in patients with schizophrenia although it remains unclear whether this neuroanatomical profile is related to the development of schizophrenia in 22q11.2 deletion carriers or whether it represents an independent manifestation of aberrant brain development. Regardless, in order to establish whether the Df(16)A þ / À mouse model shows face validity, it is critical to evaluate whether the cardinal neuroanatomical features associated with the human 22q11.2 deletions-or at least a subset of them-are faithfully recapitulated in the mouse model.
Although no gross anatomical brain abnormalities have been described in Df(16)A þ / À mice, 3,4,7 brain structure at the mesoscopic level has never previously been examined systematically. Furthermore, it has also remained unknown whether the neuroanatomical changes found in human carriers of the 22q11.2 deletions are also present in the Df(16)A þ / À mice. Therefore, we performed high-resolution MRI imaging of the Df(16)A þ / À mouse model in an effort to define observable neuroanatomical features through a whole-brain unbiased analysis. Moreover, we carried out an extensive review of the MRI neuroimaging literature through which we demonstrate that the Df(16)A þ / À mice harbor some of the most common neuroanatomical findings that have been described in human 22q11.2 deletion carriers. Our analysis confirms that the Df(16)A þ / À mouse model has strong face validity by demonstrating that it clearly recapitulates several of the essential features of the brain anatomy associated with human 22q11.2 deletions. Importantly, higher resolution magnetic resonance imaging compared with neuroimaging in human subjects allowed the detection of previously unknown subtle local differences, including ones localized to specific areas within both the deep cerebellar nuclei and the cerebellar cortex.
MATERIALS AND METHODS Mice
Mice have been described previously 5, 7, 8 and were bred at Columbia University (New York, NY, USA). Mutant mice carry a hemizygous 1.3-Mb chromosomal deficiency (Df(16)A þ / À ), which ranges from the Dgcr2 gene to Hira and spans a segment syntenic to the 1.5-Mb human 22q11.2 deletion, encompassing 27 genes. 6, 7 The mutation has been backcrossed to C57BL/6 background for over 15 generations. Twenty male mice (10 Df(16)A þ / À and 10 wild-type (WT) littermates aged 14 to 24 weeks were perfused for MRI imaging.
Specimen preparation
Mice were anesthetized with a mixture of ketamine and xylazine and then intracardially perfused with 30 ml of 0.1 M phosphate-buffered saline containing 10 U/ml heparin (Sigma, St Louis, MO, USA) and 2 mM Prohance (a gadolinium contrast agent) (Bracco Diagnostics, Monroe Township, NJ, USA). 25, 26 After perfusion, the mice were decapitated and the skin, lower jaw, ears and cartilaginous nose tip were removed. The brain was left within the skull to eliminate any deformities that would be caused by its removal. The brain within the skull was incubated overnight at 4 1C in 4% paraformaldehyde containing 2 mM of Prohance. Subsequently, the specimens were transferred to 0.1 M phosphate-buffered saline containing 2 mM Prohance and 0.02% sodium azide for at least 7 days before MRI scanning. Perfusions were conducted at the Columbia University in New York, after which the specimens were shipped overnight to the Mouse Imaging Centre (MICe) in Toronto, where they were promptly stored at 4 1C until scanning.
MRI scanning
Images were acquired on a seven Tesla MRI scanner (Varian, Pao Alto, CA, USA) with a 40 cm bore diameter. An in-house custom-built solenoid array was used to acquire all images. The solenoid array contains 16 individual transmit and receive coils, which allow the acquisition of images from 16 separate samples in one overnight session. 26, 27 Parameters used in the MRI scan were optimized for gray/white matter contrast and high efficiency.
The sequence used was a T2 weighted 3D fast spin echo, with a repetition time (TR) of 200 ms, an echo train length of 6, an effective TE of 42 ms, a field of view of 25 mm Â 28 mm Â 14 mm and a matrix size of 450 Â 504 Â 250, which leads to an isotropic resolution of 56 mM. In the first phase encode dimension, consecutive k-space lines were acquired with alternating echoes to move discontinuity-related ghosting artifacts to the edges of the field of view. 28 This sequence requires oversampling of the phase encode dimension by a factor of two to avoid the interference of these artifacts. The field of view direction was subsequently cropped to 14 mm after reconstruction. Total imaging time for the acquisition was 11.7 h. 26 
Registration and analysis
To test for any volumetric changes in Df(16)A þ / À compared with WT mice images from the MRI scans were linearly (6 parameters followed by 12 parameters) and subsequently non-linearly registered. All scans were then resampled with the appropriate transform and averaged to create a population atlas, which represents the average anatomy of all brains. Registrations were performed with a combination of the mni_autoreg tools 29 and ANTS (Advanced Normalization Tools). 30, 31 The result of this registration is to have all scans deformed into exact alignment with each other in an unbiased fashion. This allows for the analysis of the deformations needed to take each individual brain into the final atlas space, the goal being to model how the deformation fields relate to genotype. 32 The Jacobian determinants of the deformation fields are then used to estimate the volume changes in each voxel. Significant regional volume changes can then be calculated in two different ways. First, regional measurements can be calculated by registering a pre-existing classified MRI atlas on to the population atlas, which allows for the volume measurement of 62 different brain regions. The 62 regions in the classified atlas include the cortical lobes, large white matter structures (that is, the corpus callosum), ventricles, cerebellum, brain stem structures and olfactory bulbs. 33 The regions volumes were then assessed in all brains, as a percentage of total brain volume. Second, individual voxel measurements can be calculated from comparisons of the Jacobian determinants in a specific voxel between Df(16)A þ / À and WT mice. All statistical analysis was performed in the R statistical environment (www. r-project.org). Multiple comparisons were controlled for by using either the false discovery rate 34 for the regional comparisons or the threshold free cluster enhancement 35 for the voxel-wise whole-brain comparisons.
RESULTS
The total brain volume was not significantly different between Df(16)A þ / À and WT littermates mice (Df(16)A þ / À : 470 ± 16 mm 3 , WT: 468±14 mm 3 ). In order to account for individual brain sizes, relative volumes were compared between groups for the 62 different regions examined. 33 Thirteen of the 62 regions were found to be significantly different at a false discovery rate threshold of 15% (qo0.15) and 9 were found to be significantly different at 10% (qo0.10) ( Supplementary Table 1 ). Figure 1 shows the normalized percent difference for all 13 regions in comparison with WT littermates. The relative volumes of all 62 regions are shown in Supplementary Table 1 , with their percent difference and corresponding q-values. Supplementary Table 2 shows the 62 regions, divided when possible, into left and right sides. The most prominent regional changes were seen in the cerebellar cortex, cortical spinal tract, cuneate nucleus, globus pallidus, lateral olfactory tract, pontine nucleus, posterior commissure, striatum, superior olivary complex and third ventricle. Many of these brain regions are also affected in humans with 22q11.2 deletions (see discussion). Table 1 lists volumetric changes found in Df(16)A þ / À mice and compares them with the most common volumetric findings in 22q11.2 deletion carriers (with or without schizophrenia) and in subjects with schizophrenia who are not known to harbor a 22q11. (Figure 2 ). Overall, several of the core manifestations of the neuroanatomical alterations caused by 22q11.2 deletions in human subjects were also observed in the Df(16)A þ / À mice. Although certain brain structures were demonstrated to have a significant volumetric increase (striatum, globus pallidus, 3rd ventricle, and part of the frontal lobe), other regions were shown to have a significant decrease in volume (cerebellum, amygdala, and part of the frontal lobe, including the frontal association cortex). The fact that multiple hallmark neuroanatomical findings in individuals with the 22q11.2 deletion are faithfully recapitulated confirms the face validity of the Df(16)A þ / À mouse model.
In addition to volumetric measurements of the 62 different regions, we also performed a voxel-wise analysis to look at the differences within brain structures. The voxel-wise analysis revealed striking differences between the Df(16)A þ / À mice and WT littermates ( Figure 3 ). Overall, the strongest differences were found in the cerebellum. The cerebellar cortex as a whole was 5% smaller in relative volume in the Df(16)A þ / À mice, and within the cerebellum the voxel-wise analysis revealed several distinctly affected subregions. Affected bilateral hemispheric areas included the flocculous and para-flocculus, crus I dorsal surface and medial aspects of the anterior lobule. Within the vermis, lobules IV/V, IX and X showed robust volume decreases in the Df(16)A þ / À mice compared with WT mice. From these areas, the flocculus and para-flocculus were the most significantly affected areas within the cerebellum (Figure 4 ). The superior vestibular and vestibulocerebellar nuclei showed bilateral volumetric decrease as well (Figure 4c ). Figure 1 . Thirteen different regions in which the relative volume was significantly different in the Df(16)A þ / À mice compared with wildtype (WT) littermates. The relative volumes in this graph were normalized to indicate how they differ from the average WT. Error bars display the s.d. A region was deemed significant at o15% false discovery rate (FDR). Nine of these regions remained significant at a more stringent FDR of o10% ( Supplementary Table 1 ). The amygdala did not display a significant overall volumetric difference between Df(16)A þ / À and control mice. However, the voxel-wise measurements demonstrated a significant volumetric reduction of a region located in the anterior section of the amygdala (Figures 3c-e ). Reductions of amygdala volume have been described both in pediatric populations with 22q11.2 deletions 36 as well as in a longitudinal study extending from childhood to young adulthood of patients who carry 22q11.2 deletions. 37 Given previous reports of volumetric changes in the frontal lobe of individuals with 22q11.2 deletions, we expected to also find a significant difference in the frontal lobe volume of Df(16)A þ / À mice compared with WT littermates. However, the alteration in overall frontal lobe volume did not reach significance (q ¼ 0.18) ( Supplementary Table 1 ). Interestingly, when we looked at left/ right asymmetry, the left side of the frontal lobe was significantly increased in relative volume (q ¼ 0.10), whereas the right frontal lobe remained unchanged (q ¼ 0.54) (Figure 2h ). Synaptic and long-range connection deficits have been previously described within the frontal lobe of Df(16)A þ / À mice, including microscopic structural abnormalities in dendritic complexity, spine density and cell density in specific cortical layers 10, 12, 13 (Fé nelon K, MK, JAG unpublished observations). Given the abundance of evidence for cytoarchitectural abnormalities in combination with the previously observed volumetric alterations of the frontal lobe from human MR imaging studies, we examined volumetric changes in the Df(16)A þ / À mice on a voxel-wise basis solely in the frontal lobe, thus decreasing the number of statistical comparisons and highlighting significant differences within the frontal lobe. Figure 5 highlights specific locations within the frontal lobe, where volumetric differences are observed. Several areas within the frontal cortex were either decreased or increased in volume in the Df(16)A þ / À mice compared with WT littermates. One of the subregions where a volumetric deficit was observed was the frontal association cortex, where we have previously also identified significant microscopic abnormalities in spine turnover (Fé nelon K, MK, JAG unpublished observations). Notably, such opposing volumetric changes may also explain the lack of an overall significant finding across the frontal cortex as a whole. Indeed, coexistence of divergent volumetric changes of specific frontal lobe subregions is highly consistent with several neuroimaging studies on human subjects who carry the 22q11.2 deletion. 38, 39 
DISCUSSION
There has been an increasing number of quantitative MR imaging studies on human subjects who carry the 22q11.2 deletion (Table 1 ). In particular, the total brain volume in individuals with Figure 2 . Several regions are highlighted in three dimensional (3D), where similarities were found between the mouse (a) and human (b). The relative volume (% total brain volume) differences in these regions are highlighted in the bar graphs (c-h). Please note, the amygdala as a whole does not reach significance; however, highly significant decreases were found within subregions of the amygdala (seen in Figure 3 ). *indicates significance at o15% false discovery rate (FDR), ** indicates significance at o10% FDR.
Df16(A) þ / À neuroanatomical phenotypes J Ellegood et al 22q11.2 deletions has been reported to be smaller compared with healthy controls. [40] [41] [42] Furthermore, although not consistent across all human studies, some studies have demonstrated a larger reduction in white matter volume as compared with gray matter 40, 42, 43 , whereas one study reported reduction in gray matter in 22q11.2 deletion carriers with schizophrenia. 41 In the Df(16)A þ / À mice, we found no difference in the overall brain volume, including the total volume of gray or white matter (data not shown). However, in terms of specific brain regions, a number of consistent findings have emerged from neuroimaging studies of 22q11.2 deletion carriers. These include cortical atrophy, enlarged ventricles, midline deficits, increase in striatal volume, cerebellar atrophy and white matter hyperintensities. 39, 40, 44 Many of the affected brain regions, such as the frontal and cerebellar cortex as well as the striatum, have also been implicated in the development of schizophrenia as well as in other behavioral and neurological phenotypes found in 22q11.2 deletion carriers.
Importantly, a large number of these findings are faithfully recapitulated in the brain of Df(16)A þ / À mice. The striatal finding in individuals carrying a 22q11.2 deletion has been reported as both an increase in the size and asymmetry of the caudate nucleus. 39, 45 The striatal region abnormality in the Df(16)A þ / À mice was one of the strongest findings, with a 5.7% increase in relative volume (false discovery rate ¼ 5%). Using voxel-wise analysis, although there was a trend toward striatal asymmetry (left4right), this did not reach the level of significance.
In parallel with the striatal enlargement, globus pallidus volume was also found to be increased in Df(16)A þ / À mice ( þ 5.1%, false discovery rate ¼ 7%). The basal ganglia have been implicated in a wide range of neurological and neuropsychiatric disorders, including movement disorders and obsessive-compulsive disorder. In a subgroup of patients with obsessive-compulsive disorder, neuroimaging studies have demonstrated a volumetric increase of the basal ganglia. 46 Notably, 22q11.2 deletion carriers have been reported to have higher rates of obsessive-compulsive disorder. 47 Obsessive-compulsive disorder during childhood was also found to be predictive of developing schizophrenia later in life in carriers of the 22q11.2 deletion. 37 Interestingly, increased striatal volumes and a reversed right4 left asymmetry have both been reported in patients with attention-deficit hyperactivity disorder who are known to carry a 22q11.2 deletion, 45 as well as in patients with attention-deficit hyperactivity disorder in general, with unknown 22q11.2 deletion carrier status. 48 Moreover, it has previously been established that motor functioning is often impaired in children with 22q11.2 deletions. This includes both a developmental delay in motor milestones as well as deficits in motor function, which do not correlate with age (for example, visual-motor integration skills) and thus appear to reflect impaired motor function independent of any developmental delay. 49 These motor deficits could be the consequence of abnormalities in the cerebellum, basal ganglia and striatum, which together with the dorsolateral prefrontal cortex form a functionally interconnected neurocircuit. Notably, all these brain structures demonstrate volumetric changes in both human 22q11.2 deletion carriers and Df(16)A þ / À mice. Therefore, these specific volumetric abnormalities could underlie the motor deficits seen in human subjects with 22q11.2 deletions.
In the Df(16)A þ / À mice, the volumes of the lateral ventricles as well as the third and fourth ventricles were measured. Only the third ventricle ( Figure 1 ) showed a statistically significant change in volume, with an increase in relative volume of 11% (q ¼ 0.07); the lateral ventricle was also increased in size (8%, q ¼ 0.47), but this was not a statistically significant difference. Interestingly, although ventricular enlargement is not specific to the 22q11.2 deletion, it is a common neuroanatomical finding in subjects with the microdeletion, especially when they are also diagnosed with schizophrenia. 44 Ventricular enlargement is the most common brain structural abnormality in patients with schizophrenia in general. 50 Notably, of the entire ventricular system, the third ventricle is most frequently increased in volume in patients with schizophrenia. 50 Cerebellar alterations have been extensively linked to the 22q11.2 deletion in humans. Twelve different studies have reported cerebellar decrease in 22q11.2 deletion carriers with schizophrenia (Table 1) and five additional studies have found cerebellar decreases in individuals with schizophrenia in general. The majority of these studies do not address in detail the specific location of these differences within the cerebellum, but rather, report only the overall difference. Using a mouse model with demonstrated face validity is therefore advantageous as the resolution and the ability to detect very subtle differences is dramatically increased compared with neuroimaging in human subjects. 19 The cerebellar findings in Df(16)A þ / À mice are particularly instructive as they are localized to specific areas within both the deep cerebellar nuclei and the cerebellar cortex. The cerebellar cortex in the Df(16)A þ / À mice was 5% smaller than WT littermates, whereas the arbor vita of the cerebellum (that is, the white matter of the cerebellum including the deep cerebellar nuclei) was not significantly different (q ¼ 0.27). However, within both of these regions, many voxel-wise differences were found (Figures 1h-i): lobules IV/V in the anterior lobes and lobules IX and X in the posterior lobes demonstrated a more precise localization of the previously reported overall volumetric decrease. Furthermore, the most striking finding was a highly robust bilateral reduction in size of both the cerebellar flocculous and paraflocculus of the cerebellum. Although most imaging studies typically do not assess individual cerebellar subregions, the flocculus-which is part of the cerebellar tonsil-was previously observed to be significantly smaller in children who carry a 22q11.2 deletion 51 as well as patients with first-episode schizophrenia. 52 Furthermore, in the Df(16)A þ / À mice, we observed a decrease in volume of the vermis lobule IV/V, representing the caudal portion of the anterior lobe, the vermis X (nodulus), the flocculus and paraflocculus that together are known to be involved in the execution of smooth pursuit eye movements. 53 In addition, the vestibulocerebellar and superior vestibular nuclei were decreased in volume. As both nuclei and lobules are part of the vestibulo-cerebellar pathway, these structures receive sensory input through the vestibular tracts regarding balance and help facilitate eye movements through efferent connections. It is striking that several of these cerebellar structures, which together form a functional neurocircuitry unit responsible for smooth pursuit eye movements, are affected both in human subjects with 22q11.2 deletions as well as in the Df(16)A þ / À mice. In concordance with this observation, abnormalities in smooth pursuit eye movements have been described in subjects with a 22q11.2 deletion 54 as well as in patients with polymorphisms of COMT 55 and ZDHHC8, 56 both of which are genes within the 22q11.2 locus. 57 Of note, impairment in smooth pursuit eye movements is one of the most widely replicated findings in schizophrenia and is also more prevalent in unaffected first-degree relatives of patients with schizophrenia. 58 Furthermore, the cerebellum communicates with the frontal cortex via polysynaptic circuits, forming a complex topography.
In the Df(16)A þ / À mice, we observed bilateral volume reductions in the medial portions of the anterior lobule and dorsal surface of crus I lobule. Both regions connect through the thalamus to the cerebral cortex and back to the cerebellum via the pontine nuclei. 59 Involvement in the executive control network has been shown for crus I in humans, 60 whereas the anterior portion of lobule IV/V has been linked to sensorimotor tasks, involving especially the upper extremities. [60] [61] [62] The reduction of the anterior section of the amygdala in the Df(16)A þ / À mice is another finding which is consistent with the human neuroanatomical phenotype associated with the 22q11.2 deletion. The most consistent data have demonstrated a decrease in amygdala volume in individuals with 22q11.2 deletions, 36 which persists into adulthood. 37 The amygdala is known to be part of a microcircuit that gates conditioned fear across species. 63 Interestingly, Df(16)A þ / À mice exhibit robust deficits in both cued and contextual fear memory compared with WT littermates, with the cued version of the test requiring intact functioning of the amygdala, whereas the context version of the test typically requires both hippocampus and amygdala. It could therefore be that the volumetric reduction of the anterior portion of the amygdala is associated with increased anxiety disorders 64 as well as with cognitive deficits 1 in human subjects with 22q11.2 deletions. Furthermore, an event-related functional MR imaging study has also demonstrated a lack of repetition-suppression effect for fearful faces in the right amygdala in individuals with 22q11.2 deletions, suggesting a lack of amygdala modulation of fear expression in human subjects who carry the deletion. 65 A reduction in amygdala volume, 66 decreased activation in the amygdala during emotional face processing 67 and cognitive deficits such as abnormalities in fear conditioning 68 have all been described in individuals with schizophrenia. Moreover, amygdala expression of Sept5, a gene in the human 22q11.2 locus and the syntenic murine Df16A region, has been identified as a possible determinant of impaired social interaction in psychiatric disorders such as schizophrenia. 69 Differences in frontal lobe size have been reported consistently in both children and adults with the 22q11.2 deletion. 38, 39, 70 Unlike striatal and cerebellar findings, however, reports have been inconsistent. Eliez et al. 39 reported an increase in the relative volume of frontal lobe in children with the 22q11.2 deletion; however, Kates et al. 38 found that absolute frontal lobe volumes were smaller in children with 22q11.2 deletions. The relative volume of the frontal lobe was increased in the Df(16)A þ / À compared with WT littermates ( þ 3.2%, q ¼ 0.18), although not statistically significant. We did examine voxel-wise differences within the frontal lobe, however, and there were specific regions where statistically significant differences were found (Figure 3) . Specifically within the frontal lobe, we identified areas that were either significantly enlarged or decreased for which we hypothesize that such contrasting differences could be responsible for the discrepancies between studies arising from competing effects. Some of the imaging studies of 22q11.2 deletion carriers have also demonstrated volumetric changes in the parietal, temporal and occipital lobes, most of which were reported to be a loss of volume. 71 The volumetric alterations described in these studies have not always been consistent, and in the Df(16)A þ / À mice we observe no significant changes in any of these three cortical regions ( Supplementary Table 1 ).
Together, we identify a striking similarity in the specific volumetric changes of Df(16)A þ / À mice compared with human 22q11.2 deletion patients, including cortico-cerebellar, corticostriatal and cortico-limbic circuits. Functional abnormalities in this critical neural circuitry would likely lead to defective information processing, cognitive and motor deficits, and perhaps psychosis. Moreover, taken together, the MRI data of the Df(16)A þ / À mutant mice that we present in this study clearly demonstrates the face validity of this model as it captures several of the fundamental neuroanatomical characteristics of the 22q11.2 deletion. As such, neuroimaging findings in Df(16)A þ / À mice will help guide the design and interpretation of additional complementary studies, such as functional imaging studies and higher resolution cytoarchitectural analysis of the affected regions, thereby advancing our understanding of the critical pathogenic mechanisms of abnormal brain development, which ultimately lead to the emergence of 22q11.2 deletion-associated psychiatric and cognitive symptoms. This may facilitate development and testing of new treatments by evaluating the effect of these medications on the neuroanatomical abnormalities in both man and mouse.
